Synthego: Robert Deans and John Tan
Synthego has appointed Robert Deans as CSO and John Tan as chief operating officer.
Deans has more than 25 years of experience developing stem cell and gene therapies, as well as translational science and global regulatory expertise. He previously served in executive roles at BlueRock Therapeutics and Rubius Therapeutics, where he participated in the creation of next-generation therapies through the use of pluripotent stem cell biology and gene editing tools, Synthego said.
Tan has decades of global operations and automation expertise in various technology and life sciences companies, including Amazon and Thermo Fisher Scientific. At Thermo Fisher, he managed global planning, quality, regulatory, procurement, supply chain, and continuous improvement functions across more than 20 sites in the US, Europe, and Asia.